NEW YORK — Lumos Diagnostics said on Wednesday that it has signed a Canadian distribution agreement for its FebriDx point-of-care acute respiratory infection assay with Winnipeg-based Northern Diagnostics.
Financial and other terms of the deal were not disclosed.
FebriDx is a single-use test designed to assess levels of two protein biomarkers in fingerstick blood samples to determine if a patient has an acute respiratory infection and if that infection is bacterial or viral. Results are provided within 10 minutes and can help guide antibiotic prescription decision making, according to Lumos.
About a year ago, a study was published indicating that FebriDx can contribute to antimicrobial stewardship initiatives associated with respiratory conditions while providing substantial savings for health systems.
Sarasota, Florida-based Lumos raised about $33.0 million through separate financing rounds in February and October last year.